CRSP vs REGN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

REGN is the larger of the two ($93.98B market cap): the incumbent the market prices for continued execution (12.85x forward earnings, beta 0.09). CRSP is the smaller challenger ($4.53B), priced similarly on forward earnings (-12.72x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

CRSP vs REGN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCRSPREGNWhat it tells you
Market cap$4.53B$93.98BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-12.7212.85Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.900.09Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range13% of range79% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.742.72How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how CRSP and REGN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRSP and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRSP and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does CRISPR Therapeutics AG (CRSP) do?

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.

Full CRSP guide

What does Regeneron Pharmaceuticals (REGN) do?

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base. Total revenue then stepped up to about $4.29 billion in Q2 2026, up roughly 17% year over year, taking trailing twelve-month revenue to about $15.5 billion and net income to about $4.3 billion.

Full REGN guide

CRSP vs REGN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • CRSP drivers: First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential.
  • REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $13.4 million over the twelve months to June 2026. For REGN, the clearest risk is Eylea biosimilar erosion.

CRSP or REGN: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CRSP if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CRSP and REGN guides.

CRSP vs REGN: the full fundamentals

CRSP. Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based multiples like P/E are negative and not analytically useful; the company is better evaluated on cash runway, Casgevy adoption, and the risk-adjusted value of its pipeline. Market cap of about $4.9 billion less roughly $1.6 billion of net cash leaves an enterprise value near $3.3 billion, which reflects significant execution uncertainty. Targets remain widely spread, from UBS at $52 to a consensus mean near $86.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron has beaten EPS estimates in each of the last four quarters, most sharply in Q2 2026 (about $14.29 against $10.21), and the shares rose about 18% over three months to roughly $794, up about 40% over a year. Consensus for Q3 2026, due October 30, sits near $16.06 of EPS on about $4.54 billion of revenue, and the ~13x forward P/E reflects the market weighing strong Dupixent growth against Eylea biosimilar erosion expected to accelerate around the fourth quarter of 2026.

Headline figures (approximate, October 2026): CRSP shows revenue (ttm to jun 30, 2026) ~$13.4 million (Q2 2026 ~$10.2 million), revenue (full year 2025) ~$3.5 million, net loss (ttm) ~$451 million; Q2 2026 ~$91 million, eps (q2 2026, actual vs estimate) -$0.94 vs -$1.18; REGN shows total revenue (ttm) ~$15.5 billion, q2 2026 total revenue ~$4.29 billion (up ~17% YoY), q2 2026 eps vs estimate ~$14.29 vs ~$10.21, net income (ttm) ~$4.3 billion (~28% net margin).

The bottom line: CRSP vs REGN

CRSP and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRSP and REGN exposure against your real portfolio. It is not an investment adviser.

Wondering how CRSP or REGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about CRISPR Therapeutics AG

Ask Walnut's AI anything about CRSP and see how it fits what you own.

FAQ

What is the difference between CRSP and REGN?

+

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CRSP or REGN the better stock?

+

Neither is universally better. REGN is the larger incumbent; CRSP is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CRSP or REGN?

+

On forward P/E (as of November 2026), CRSP trades at -12.72x and REGN at 12.85x, so CRSP is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CRSP and REGN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CRSP vs REGN?

+

CRSP: The commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $13.4 million over the twelve months to June 2026. The expiration of CRISPR's cost-deferral agreement with Vertex drove collaboration expenses up roughly 77 percent year over year in 2025, contributing to a full-year operating loss of approximately $665 million, and the company must repay around $222 million in previously deferred costs before net cash flows from Casgevy accrue to CRSP shareholders. The convertible notes add about $784 million of debt that will eventually need to be repaid or converted, with dilution risk if conversion happens. Competing gene-editing and cell-therapy platforms from Intellia Therapeutics, Beam Therapeutics, and large pharmaceutical companies pursuing in vivo approaches could erode CRSP's differentiation over time. The share price, down about 26% over the past year, reflects meaningful skepticism about the pace of the commercial ramp, and binary clinical readouts such as CTX310 can move it sharply in either direction. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CRSP or REGN; figures are approximate and dated (as of November 2026). Verify current data before investing.